Piotrowsky Alban, Burkard Markus, Hammerschmidt Katharina, Ruple Hannah K, Nonnenmacher Pia, Schumacher Monika, Leischner Christian, Berchtold Susanne, Marongiu Luigi, Kufer Thomas A, Lauer Ulrich M, Renner Olga, Venturelli Sascha
Department of Nutritional Biochemistry, Institute of Nutritional Sciences, University of Hohenheim, Garbenstrasse 30, 70599 Stuttgart, Germany.
Department of Medical Oncology and Pneumology, Virotherapy Center Tuebingen (VCT), Medical University Hospital, 72076 Tuebingen, Germany.
Antioxidants (Basel). 2024 Sep 10;13(9):1095. doi: 10.3390/antiox13091095.
Several studies have demonstrated, both in vitro and in animal models, the anti-tumor efficacy of high-dose ascorbate treatment against a variety of tumor entities, including glioblastoma, the most common and aggressive primary malignant brain tumor. The aim of this study was to investigate the effects of high-dose ascorbate as well as dehydroascorbic acid on human glioblastoma cell lines and to evaluate different treatment conditions for the combined administration of ascorbate with magnesium (Mg) and iron (Fe). Intracellular levels of reactive oxygen species and the induction of cell death following ascorbate treatment were also investigated. We demonstrated high cytotoxicity and antiproliferative efficacy of high-dose ascorbate in human glioblastoma cells, whereas much weaker effects were observed for dehydroascorbic acid. Ascorbate-induced cell death was independent of apoptosis. Both the reduction in cell viability and the ascorbate-induced generation of intracellular reactive oxygen species could be significantly increased by incubating the cells with Fe before ascorbate treatment. This work demonstrates, for the first time, an increase in ascorbate-induced intracellular ROS formation and cytotoxicity in human glioblastoma cells by pre-treatment of the tumor cells with ferric iron, as well as caspase-3 independence of cell death induced by high-dose ascorbate. Instead, the cell death mechanism caused by high-dose ascorbate in glioblastoma cells shows evidence of ferroptosis. The results of the present work provide insights into the efficacy and mode of action of pharmacological ascorbate for the therapy of glioblastoma, as well as indications for possible approaches to increase the effectiveness of ascorbate treatment.
多项研究已在体外和动物模型中证明,高剂量抗坏血酸治疗对包括胶质母细胞瘤(最常见且侵袭性最强的原发性恶性脑肿瘤)在内的多种肿瘤实体具有抗肿瘤功效。本研究的目的是调查高剂量抗坏血酸以及脱氢抗坏血酸对人胶质母细胞瘤细胞系的影响,并评估抗坏血酸与镁(Mg)和铁(Fe)联合给药的不同治疗条件。还研究了抗坏血酸处理后细胞内活性氧水平及细胞死亡的诱导情况。我们证明了高剂量抗坏血酸对人胶质母细胞瘤细胞具有高细胞毒性和抗增殖功效,而脱氢抗坏血酸的作用则弱得多。抗坏血酸诱导的细胞死亡与凋亡无关。在抗坏血酸处理前用铁孵育细胞,可显著增加细胞活力的降低以及抗坏血酸诱导的细胞内活性氧的生成。这项工作首次证明,用三价铁预处理肿瘤细胞可增加抗坏血酸诱导的人胶质母细胞瘤细胞内活性氧的形成和细胞毒性,以及高剂量抗坏血酸诱导的细胞死亡不依赖于半胱天冬酶 - 3。相反,高剂量抗坏血酸在胶质母细胞瘤细胞中引起的细胞死亡机制显示出铁死亡的证据。本研究结果为药理抗坏血酸治疗胶质母细胞瘤的疗效和作用方式提供了见解,也为提高抗坏血酸治疗效果的可能方法提供了线索。